Inflammation and hemostasis: A bidirectional interaction

Clinical Laboratory

Volumn 53, Issue 1-2, 2007, Pages 63-67

  Franchini, Massimo ^a   Veneri, Dino ^b   Lippi, Giuseppe ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Coagulation; Inflammation; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; FIBRINOGEN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE PHASE RESPONSE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD CLOTTING; COMPLEMENT ACTIVATION; DOWN REGULATION; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFLAMMATION; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PROTEIN SYNTHESIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS; UPREGULATION; VASCULAR DISEASE;

BLOOD COAGULATION; HEMOSTASIS; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 33847613816     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Esmon CT. Infflammation and thrombosis. J Thromb Haemost 2003, 1: 1343-8.
2. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005, 131: 417-30.
3. Opal SM. Interactions between coagulation and inflammation. Scand J Infect Dis 2003; 35: 545-54.
4. Schoenmakers SHHF, Reitsma PH, Spek CA. Blood coagulation factors as inflammatory mediators. Blood Cells Mol Dis 2005, 34: 30-7.
5. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
6. Monroe DM, Hoffman M, Olk JA, Roherts HR. Platelet activity of high-dose factor VIIa is independent Of tissue factor. Br J Haematol 1997, 99: 542-7.
7. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable filbrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
8. Chu AJ. Tissue factor mediates inflammation. Arch Biochem Biophysics 2005: 440 123-32.
9. Camerer E, Rottingen JA, Gjernes E, et al. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem 1999; 274: 32225-33.
10. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005,15:254-9.
11. Amaral A, Opal SM, Vincent JL. COagulation in sepsis. Intensive Care Med 2004; 30: 1032-40.
12. Han KH, Hong KH, Park JH, et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2o04; 109: 2566-71.
13. Cermak J, Key NS. Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993:82: 513-20.
14. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipopiotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-42.
15. Afshar-Kharghan V, Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol 2006; 13: 34-9.
16. Burstein SA. Cytokines, platelet production and hemostasis. Platelets 1997; 8: 93-104.
17. van der Poll T, Levi M, BUller HR. et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174: 119-32.
18. Biemond BJ, Levi M, Ten Cate H, et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci 1995: 88: 587-94.
19. Yamamoto K. Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasmiogen activator. J Clin Invest 1996; 97: 2440-51.
20. Rhee JS, Santoso S, Herrmann M, et al. New aspects of integrin-mediated leukocyte adhesion in inflammation: regulation by haemostattic factors and bacterial products. CUrr Mol Med 2003; 3: 387-92.
21. Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-43.
22. Loskutoff DJ, Curriden SA, Hu G. Deng G. Regulation of cell adhesion by PAI-1. APMIS 1999; 107: 54-61.
23. Szaba FM, Smiley ST. Roles Im thrombin and fibrin(ogen) in cytokine,chemokine production and macrophage adhesion in vivo. Blood 2002; 99: 1053-9.
24. Opal SM. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 2000; 28: S34-7.
25. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C recaptor. J Biol Chem 1994: 269: 26486-91.
26. Fisher CJ, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000; 28: S49-S56.
27. Okajima K. Regulation of inflammatory responses by natural anti-coagulants. Immunol Rev 2001; 184: 258-74.
28. Campbell W, Okada N, Okada H. Carboxypeptidase R is an inactivator of complement-delivered inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 2001; 180: 162-7.
29. Conway EM, Van de Wouver M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaβ and mitogen-activated protein kinase pathways. J Exp Med 2002, 196: 565-77.
30. White B, Schmidt M, Murphy C, et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 2000; 110: 130-4.
31. Kurosava S, Esmon CT, Stearns-Kurosawa DJ. The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol 2000; 165: 4697-703.
32. Bernard GR, Vincent JL, Laterre re PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Ffficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
33. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-93.
34. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000: 95: 1124-9.
35. Abiahani E, Reinhart K, Opal S, et al; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238-47.
36. Levi M, van der Poll T, Miller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-704.
37. Spronk HM, van der Voorl D, Ten Cate H. Blood coagulation and the risk of atherothrombosis: a complex relationship. Thromb J 2004: 2: 12.
38. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169: 203-14